Back to News
Market Impact: 0.15
Johnson & Johnson Reports Sustained Two-Year ICOTYDE Results In Plaque Psoriasis
Source: Nasdaq
Healthcare & Biotech
Johnson & Johnson reported two-year results from the Phase 3 ICONIC-LEAD study of ICOTYDE (icotrokinra) in adults and adolescents aged 12 and older with moderate-to-severe plaque psoriasis. The provided article text is truncated and does not state the study outcomes or any numerical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
- What's behind the recovery rally in tech stocks — plus, Elon Musk's very good week
- Earnings season kicks into high gear as big banks report next week. Here's what's ahead
- Cramer’s week ahead: Earnings kick off as banks and chipmakers face big tests
- Jim Cramer's top 10 things to watch in the stock market Friday
- Teva wins FDA approval for monthly schizophrenia injection Weltruza